Denali Therapeutics
PublicDenali Therapeutics is now publicly traded
The data on this page reflects Denali Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Dec 7, 2017
Last Round
Follow-on Offering
Dec 10, 2025
Total Funding Raised
$1.61B
Company Overview
Denali Therapeutics is a biotechnology company that discovers and develops innovative biotherapeutics designed to cross the blood-brain barrier for the treatment of neurodegenerative and lysosomal storage diseases.
Sector
Biotech
AI Layer
Non-AI
Keywords
Denali Therapeutics Comparables
Compare Denali Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Atacama Therapeutics, Inc. | 63% | |
| Anacalypsis Therapeutics | 59% | |
| Kurve Therapeutics, Inc. | 59% |
For institutional investors. Book with your work email.
Denali Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Dec 10, 2025 | ||||
| Strategic | Dec 4, 2025 | ||||
| PIPE | Feb 27, 2024 | ||||
| IPO | Dec 7, 2017 | ||||
| Series B | Aug 25, 2016 | ||||
Series A | May 14, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Denali Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Morgan Stanley & Co., LLC | Follow-on Offering |
| F-Prime Capital | Series B, Series A |
| Biomatics Capital Partners | Series A |
| Morgan Stanley | IPO |
| ARCH Venture Partners | Series B, Series A |
| Royalty Pharma | Strategic |
| Goldman Sachs & Co. LLC | IPO, Follow-on Offering |
For institutional investors. Book with your work email.
Denali Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.